Furthermore, the IC50 of lapatinib, a HER-2 and EGFR tyrosine kinase inhibitor, is significantly negatively correlated with the CHPsigP score in breast (r=-0.457, P<0.001) and gastric cancer (r=-0.529, P=0.004) (Figure 5B). This evidence concerns the gene EGFR and gastric cancer.